Company recommends dividend of 15% – Rs. 1.5 per share for FY 21
- Net Revenues from operations in Q4FY21 at Rs. 77.54 crore, up 3.03% from Rs. 75.26 crore in Q4FY20
- Profit before Tax in Q4FY21 at Rs. 14.79 crore, up 29.94% from Rs. 11.38 crore in Q4FY20
- Exports in FY21 at Rs. 266.20 crore, up 17.79% from Rs. 225.99 crore in FY20
Financial Highlights (Standalone)
(Amount in Cr except EPS)
| Q4 FY21 | Q4 FY20 | Y-O-Y | FY21 | FY20 | Y-O-Y | |
| Net Revenue from Operations | 77.54 | 75.26 | 3.03% | 413.05 | 376.09 | 9.83% |
| EBITDA | 16.74 | 13.05 | 28.25% | 88.12 | 71.50 | 23.24% |
| Profit before Tax | 14.79 | 11.38 | 29.94% | 81.01 | 64.05 | 26.49% |
| Net Profit | 11.85 | 9.23 | 28.33% | 60.41 | 49.56 | 21.88% |
| E.P.S (Rs.) | 5.92 | 4.62 | 28.33% | 30.20 | 24.78 | 21.88% |
Ahmedabad, May 26, 2021: Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies has reported net profit of Rs. 11.85 crore in Q4FY21 as against net profit of Rs. 9.23 crore in the corresponding period last year, growth of 28.33%. Net revenue from operations in Q4FY21 was reported at Rs. 77.54 crore, higher by 3.03% over previous fiscal’s same period net revenue from operations of Rs. 75.26 crore. Company reported EBITDA of Rs. 16.74 crore in Q4FY21, rise of 28.25% as compared to Rs. 13.05 crore in the corresponding period last year. EPS for Q4FY21 was at Rs. 5.92 per share as compared to Rs. 4.62 in the corresponding period last year. Company has recommended dividend of 15% – Rs. 1.50 per share on the face value of Rs. 10 per share.
During the fiscal, promoter group of Lincoln Pharmaceuticals Ltd increased holding in the company to 37.25% – rise of 4.9% (490 bps) from 32.36% as of 31 March 2020. Promoter group bought 9.8 lakh shares from the secondary market during the year. Backed by improvement in the company’s financial risk profile, steady growth in scale & margins, healthy profitability, rating agency ICRA has upgraded the company’s long-term and short-term bank facilities to A and A1 respectively.
Commenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, “Company’s performance during the quarter and full year has been quite robust and considering that have recommended dividend of Rs. 1.50 per share. Company is growing strength to strength, delivering robust operational and financial performance maintaining healthy growth in revenue, margins and profitability. We expect the growth momentum to continue in coming years. Our strategic growth initiatives, product and geographical expansion, operational efficiency are likely to maximise value for all stakeholders in the near to medium term.”
Company is witnessing good traction in the export business, which is expected to get further boost once EU operations begins. Company plans to enter the EU markets in FY22 with its dermatology, gastro and pain management products. Company currently exports to more than 60 countries and plans to expand to 90 plus countries. For the next phase of growth, company is building a strong portfolio in lifestyle and chronic segment especially dermatology, gastro and pain management to complement its strong presence in acute segment.
Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP and ISO-9001: 2015. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, ant-diabetic, anti-malaria among others. Company has filled 25 plus patent applications and is awarded with seven patents. Company has a strong presence in domestic market with good strength of own field force and also exports to more than 60 countries.
Corporate Comm India (CCI Newswire)
